Background: Individuals at ultra-high risk (UHR) for psychosis are understood to be the putative prodrome of overt psychosis, although there is still a possibility of false positives. The aim of the present study is to examine the potential links between multi-dimensional schizotypy, basic symptoms and emerging psychosis as defined by positive symptoms in individuals at ultra-high risk (UHR) for psychosis. Method: Sixty-one UHR individuals and 41 healthy controls were participated in baseline assessments. For multi-dimensional schizotypy assessments, Chapman's perceptual aberration scale, magical ideation scale, revised physical and social anhedonia scales, schizotypal ambivalence scales, and Eysenck's impulsiveness scale were used. Basic symptoms were assessed by using the schizophrenia-specific items of the Frankfurt complaints questionnaire (FCQ). Results: Individuals at UHR showed higher schizotypy scores and basic symptoms at baseline. The transition rate of overt psychosis was 36.4 % at 4 years of follow-up. Cox regression analysis showed that the basic symptoms (HR 1.456, p = 0.025) and impulsiveness (HR 1.175, p = 0.039) were significant predictors of transition into overt psychosis in UHR individuals [χ 2 (4) =14.242, p = 0.007].
Abstract
Introduction: Poor adherence to medication is one of the leading causes of relapse in schizophrenia. Several determinants have been proposed as reasons for noncompliance. Insight and Quality of doctor-patient relationship seems to be important determinants in compliance. Only few studies investigated the role. We examined the relationships between medication adherence and clinical variables with schizophrenia in Korea. Method: 81 clinically stable outpatients diagnosed as schizophrenia were participated. To evaluate medication adherence, Korean version of medication adherence rating scale(KMARS) was used. Korean version of Scale To Assess the Therapeutic Relationship(STAR-K) was used to check quality of therapeutic alliance. STAR-K consists of two subscales, 'positive collaboration' and 'Non-supportive clinical input'. Insight to illness was assessed with Korean version of Scale to Assessment of Unawareness of Mental disorder(K-SUMD). There are 3-items in KSUMD, each item evaluate awareness in mental disorder(item1), the achieved effects of medication(item2) and consequences of mental disorder(item3). Correlations and regression analyses were calculated between KMARS, STAR-K and K-SUMD Results: KMARS total score was correlated with STAR-K total score(r=0.235, p<0.05), STAR-K non-supportive clinical input(r=0.367, p<0.01), K-SUMD item1(r=-0.228, p<0.05) and item2(r=-0.256, p<0.05). The regression performed testing K-SUMD(item1), K-SUMD(item2) and STAR-K non-supportive clinical input as independent variables and KMARS total score as a dependent variable. Result shows that K-SUMD(item2) and STAR-K explained 13.2% of the variance. (p=0.001) Conclusions: Good therapeutic alliance was associated with better therapeutic adherence in outpatient clinic. Especially, nonsupportive attitudes of clinicians linked to lower adherence. Making patients feel that the clinicians are supportive could improve the adherence rate. Considering insight into illness, awareness in mental disorder and achieved effects of medication was associated with adherence rate.
Moreover, subjective response in medication was not associated with insight. It suggests that patients with high awareness in need for treatment, the response of medication could influence small portion in adherence.
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Early Cannabis Use Effects on Frontal Cortical Gamma Oscillations in First Episode Psychosis
Raymond Cho 1 , Srihari Banaglore 2 , David Lewis 2 , Debra Montrose 2 , Nicola Polizzotto 1 , Christopher Walker 1 1 University of Texas Health Science Center at Houston, USA, 2 University of Pittsburgh, USA Abstract Cognitive control -a system that modulates the operation of other cognitive in the service of goal-directed behavior -is a core deficit in schizophrenia and its association with frontal cortical gamma oscillatory disturbances suggests a way to integrate molecular findings and models of cognition. Here we present data from first episode patients and address the role of concurrent cannabis usage in cognitive control impairments and its neurophysiological markers. 62 healthy controls were compared to 101 first episode patients performing the Preparing to Overcome Prepotency (POP) task, a cued stimulus-response reversal task, which in chronic schizophrenia patients, has been shown reduced engagement of prefrontal gamma activity. Psychosis subjects included patients with schizophrenia, schizoaffective disorder as well as other psychosis spectrum disorders, and had a variable history of cannabis usage. Patients showed impaired performance and complex spectral alterations of EEG activity. This included reduction of gamma activity in the frontal electrodes during high-control trials. However in the patient group, significant variability was explained by cannabis usage history. In particular a greater gamma power impairment was observed for subjects who had greater lifetime cannabis usage and heavy earlier cannabis use (<16 years old) appeared to exert a more deleterious effect than later use or more minimal use. The findings of this study suggest that the presence and time course of cannabis use history in first episode psychosis has a significant deleterious impact on frontal cortical gamma oscillations in the context of a cognitive control task. Cannabis effects during development are recognized as a critical area in psychosis research, possibly implicated in the genesis, presentation of the disorder and/or serving as an important confounding factor. The present data highlights how the development of specific and accurate models of cognitive impairment in psychosis
